European Journal of Biomedical and Pharmaceutical Sciences

A REVIEW ON CARDIAC HYPERTROPHY & TREATMENT STRATEGY

Rahul Jaiswal*, Dr. Amit Kishor Srivastava, Gulab Chandra, Dr. Rohit Mohan, Dr. Amresh Gupta and Rupali Jaiswal

ABSTRACT

The heart is capable of answering to stressful situations by extending muscle mass, which is broadly defined as cardiac hypertrophy. This process decreases ventricular wall stress for the heart undergoing a greater than normal workload. In starting stage, cardiac hypertrophy is associated with normal or increased cardiac function and is considered to be adaptive or physiological; while, at later stages, if the stimulus is not removed, it is affiliated with contractile dysfunction and is termed pathological cardiac hypertrophy. The exercise-induced extend in the capacity of pumping blood leads to thickening of the ventricle wall, insinuated as physiological hypertrophy, while the reduced capacity of pumping blood as a result of hypertension and volume overload on the heart indicates pathological hypertrophy. The prevention master plan for cardiac hypertrophy involves both surgically and medicinally like thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin (Ang) II receptor blockers, beta-blockers, and calcium channel blockers. In this review, we focus on significant knowledge regarding cardiac hypertrophy and current emerging approaches to forbid hypertrophy with the ultimate goal to prevent or delay the onset of heart failure and sudden death in patients.

Keywords: Cardiac hypertrophy, Physiological cardiac hypertrophy, Pathological cardiac hypertrophy, Treatment.